The crux of the matter: Did the ABC’s catalyst program change Statin use in Australia?

Medical Journal of Australia

Volumn 202, Issue 11, 2015, Pages 591-595

  Schaffer, Andrea L ^a   Buckley, Nicholas A ^a   Dobbins, Timothy A ^a   Banks, Emily ^b   Pearson, Sallie Anne ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP INHIBITOR;

AGED; ARTICLE; DEMENTIA; DIABETES MELLITUS; DRUG DISTRIBUTION; DRUG SAFETY; DRUG USE; FEMALE; HEALTH PROGRAM; HEART DISEASE; HUMAN; MALE; AUSTRALIA; DRUG UTILIZATION; PRACTICE GUIDELINE; PROGRAM EVALUATION; STATISTICS AND NUMERICAL DATA;

AGED; AUSTRALIA; DRUG UTILIZATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PRACTICE GUIDELINES AS TOPIC; PROGRAM EVALUATION;

EID: 84931079058     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja15.00103     Document Type: Article

References (24)

1. Australian Broadcasting Corporation. Catalyst. Heart of the matter. Sydney: ABC, 2014. http://www.abc.net.au/catalyst/heartofthematter (accessed Apr 2015).
2. Australian Broadcasting Corporation. Media Watch. Catalyst challenges the mainstream. Sydney: ABC, 2013. http://www.abc.net.au/mediawatch/transcripts/s3888657.htm (accessed Jan 2015).
3. National Heart Foundation of Australia. The National Heart Foundation of Australia’s summary of the recommendations for cholesterol management. Canberra: NHF, 2014. http://www.heartfoundation.org.au/SiteCollectionDocuments/Heart%20Foundation%20summary%20of%20recommendations%20for%20cholesterol%20management%20-%20Catalyst%20-%20FINAL.pdf (accessed Mar 2014).
4. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. 2013. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2889-2934.
5. Australian Government Department of Health. Australian Statistics on Medicines 2011. Canberra: Department of Health, 2013. http://www.pbs.gov.au/statistics/asm/2011/australianstatistics-on-medicines-2011.pdf (accessed Jul 2014).
6. Morgan TK, Williamson M, Pirotta M, et al. A national census of medicines use: a 24-hour snapshot of Australians aged 50 years and older. Med J Aust 2012; 196: 50-53.
7. (accessed May 2014).
8. National Heart Foundation of Australia. Cholesterol still important risk factor for heart disease. Sydney: NHF, 2013. http://www.abc.net.au/mediawatch/transcripts/1341_heartfoundation1.pdf (accessed Mar 2014)
9. National Heart Foundation of Australia. The impact of ‘ABC Catalyst’ on lipid modifying medication use. Sydney: NHF, 2013. http://www.heartfoundation.org.au/news-media/Media-Releases-2013/Documents/The%20Impact%20of%20ABC%20Catalyst%20on%20Lipid%20Modifying%20Medication%20Use%20Survey%202013.pdf (accessed Dec 2014)
10. Australian Capital Territory Medicare Local. Statin use survey results. Canberra: ACTML, 2014. http://www.actml.com.au/Uploads/Documents/Statin%20use%20survey%20results_20140401115619.pdf (accessed Jan 2015).
11. Donnelly N, McManus P, Dudley J, Hall W. Impact of increasing the resupply interval on the seasonality of subsidised prescription use in Australia. Aust N Z J Public Health 2000; 24: 603-606.
12. Box GEP, Jenkins GM, Reinsel GC. Time series analysis: forecasting and control. 4th ed. Hoboken, NJ: John Wiley, 2008.
13. Australian Government Department of Health. PBS and RPBS Section 85. Date of Processing and Date of Supply Data. Canberra: Department of Health, 2014. http://www.pbs.gov.au/info/statistics/dos-and-dop/dos-and-dop (accessed Jan 2015).
14. Corderoy A. “Miracle” drugs put thousands at risk. Sydney Morning Herald 2012; 1. Mar. http://www.smh.com.au/national/health/miracle-drugs-put-thousands-at-risk-20120229-1u3ia.html (accessed Nov 2014).
15. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
16. Cholesterol Treatment Trialists’ (CTT) Collaborators; Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-590.
17. National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. Sydney: National Stroke Foundation, 2012. http://strokefoundation.com.au/site/media/AbsoluteCVD_GL_webready.pdf (accessed Mar 2015).
18. Heeley EL, Peiris DP, Patel AA, et al. Cardiovascular risk perception and evidence–practice gaps in Australian general practice (the AusHEART study). Med J Aust 2010; 192: 254-259.
19. Wei L, Ebrahim S, Bartlett C, et al. Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ 2005; 330: 821.
20. Cholesterol Treatment Trialists’ (CTT) Collaborators; Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-125.
21. Australian Broadcasting Corporation. Catalyst ‘Heart of the Matter’ Investigation Report. Canberra: ABC, 2014. http://about.abc.net.au/wp-content/uploads/2014/05/Catalyst-Heart-of-the-Matter-ACAInvestigation-Report.pdf (accessed Dec 14).
22. Casula M, Tragni E, Catapano AL. Adherence to lipid-lowering treatment: the patient perspective. Patient Prefer Adherence 2012; 6: 805-814.
23. Sambrook PN, Chen JS, Simpson JM, March LM. Impact of adverse news media on prescriptions for osteoporosis: effect on fractures and mortality. Med J Aust 2010; 193: 154-156.
24. Lagarde M. How to do (or not to do). assessing the impact of a policy change with routine longitudinal data. Health Policy Plan 2012; 27: 76-83.